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Background: This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6
(mFOLFOX6) in first-line treatment of locally advanced or metastatic colorectal cancer (mCRC).
Methods: Patients received 800-mg intravenous necitumumab (day 1; 2-week cycles), followed by oxaliplatin 85mgm 2, folinic
acid 400mgm 2, and 5-fluorouracil (400mgm 2 bolus then 2400mgm 2 over 46 h). Radiographic evaluation was performed
every 8 weeks until progression. Primary endpoint was objective response rate.
Results: Forty-four patients were enrolled and treated. Objective response rate was 63.6% (95% confidence interval 47.8–77.6);
complete response was observed in four patients; median duration of response was 10.0 months (7.0–16.0). Median overall survival
(OS) and progression-free survival (PFS) were 22.5 (11.0–30.0) and 10.0 months (7.0–12.0), respectively. Clinical outcome was better
in patients with KRAS exon 2 wild type (median OS 30.0 months (23.0–NA); median PFS 12.0 (8.0–20.0)), compared with KRAS exon
2 mutant tumours (median OS 7.0 months (5.0–37.0); median PFS 7.0 (4.0–18.0)). The most common gradeX3 adverse events were
neutropenia (29.5%), asthenia (27.3%), and rash (20.5%).
Conclusion: First-line necitumumabþmFOLFOX6 was active with manageable toxicity in locally advanced or mCRC; additional
evaluation of the impact of tumour RAS mutation status is warranted.
Colorectal cancer (CRC) is the third most common form of cancer
in men and the second most common form of cancer in women
worldwide (Ferlay et al, 2013). An estimated annual total of 1.4
million cases will be diagnosed, leading to B694 000 deaths per
year (B8.5% of all cancer-related deaths). Approximately, 25% of
CRC cases are overtly metastatic at diagnosis, and B50% of
patients will ultimately develop recurrent or metastatic disease
(Van Cutsem et al, 2014).
Many phase II–III trials have investigated the addition of an
epidermal growth factor receptor (EGFR) monoclonal antibody
(mAb) to a first-line FOLFOX (oxaliplatin, folinic acid and
5-fluorouracil (5-FU)) combination in patients with KRAS exon 2
wild-type metastatic CRC (mCRC). The phase III PRIME study
(Douillard et al, 2010, 2014) and the randomised phase II OPUS
study (Bokemeyer et al, 2011) evaluated the FOLFOX4 regimen
in combination with panitumumab and cetuximab, respectively.
In these studies, objective response rate (ORR) and progression-free
survival (PFS) were significantly improved with the addition of an
EGFR mAb to FOLFOX4 among patients with tumours assessed as
wild type at codons 12 and 13 of KRAS exon 2; in the PRIME study, a
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significant improvement in overall survival (OS) was also observed.
Extended mutation analyses of additional tumour RAS loci (KRAS
exons 3 and 4, and NRAS exons 2, 3 and 4) suggested that the efficacy
benefit was further restricted to patients with tumours wild type at all
screened loci (Douillard et al, 2013; Bokemeyer et al, 2015). In both the
PRIME and OPUS studies, a negative effect on efficacy was
reported from combining an EGFR mAb with FOLFOX4 among
patients whose tumours harboured a RAS mutation (Douillard
et al, 2010, 2013; Bokemeyer et al, 2011, 2015). On the basis of
additional evidence showing anti-EGFR antibodies were unlikely
to benefit patients with this disease whose tumours carry KRAS
mutations (Amado et al, 2008; Karapetis et al, 2008), the phase
III COIN trial evaluated the addition of cetuximab to oxaliplatin-
based chemotherapy (oxaliplatin plus capecitabine or oxaliplatin
plus fluorouracil and folinic acid) in first-line treatment of
patients with advanced CRC with KRAS wild-type tumours
(Maughan et al, 2011). In this trial, cetuximab increased the
response rate; no evidence of benefit in PFS or OS was seen.
On the basis of these data, FOLFOX4 in combination with
either panitumumab or cetuximab is recommended in Europe and
the United States for the first-line treatment of patients with RAS
wild-type mCRC only (NCCN).
Necitumumab (LY3012211; IMC-11F8) is a second-generation
recombinant human EGFR mAb of the immunoglobulin G1 class,
which demonstrates a high affinity for EGFR and blocks ligand-
induced receptor phosphorylation and downstream signalling
(Liu et al, 2004). In vitro studies further demonstrate that
necitumumab inhibits EGFR-dependent tumour cell proliferation,
and can exert cytotoxic effects in tumour cells through antibody-
dependent cell-mediated cytotoxicity. Necitumumab has also been
shown to block tumour growth in CRC xenograft models in
combination with chemotherapy (Prewett et al, 2004).
The dose and treatment schedule used for necitumumab in the
current study was based on safety and pharmacokinetic data from
a phase I study in 60 heavily pretreated patients with advanced
solid tumours (Kuenen et al, 2010). This study established the
maximum tolerated dose of necitumumab and the recommended
dose for further clinical development to be 800mg, administered
intravenously (i.v.), either weekly or every second week. The major
dose-limiting toxicity was grade 3 headache. The most common
drug-related adverse events (AEs) were typical for this class of
agent and consisted predominantly of skin reactions, headache,
nausea/vomiting, and fatigue (mostly grade 1 or 2). Importantly,
no hypersensitivity or infusion reactions associated with necitu-
mumab were reported in this trial.
The present phase II study was designed to investigate necitumu-
mab in combination with a modified version of the FOLFOX6 regimen
(mFOLFOX6) and was initiated following preliminary reports (later
reported in full) of encouraging activity and safety associated with
cetuximab in combination with oxaliplatin-based chemotherapy
(Tabernero et al, 2007; Boccia et al, 2010). Evidence at that time from
small single-arm studies in chemorefractory mCRC suggested that
responses to treatment with cetuximab were confined to patients whose
tumours did not harbour KRAS codon 12 or 13 (exon 2) mutations (Di
Fiore et al, 2007; De Roock et al, 2008; Lievre et al, 2008). These
findings were later confirmed in larger randomised studies conducted
in the first-line setting (Bokemeyer et al, 2011; Van Cutsem et al, 2011;
Douillard et al, 2014). Accordingly, in March 2008, the protocol for the
present study was amended to include evaluation of tumour mutation
status at KRAS codons 12 and 13 among enrolled patients.
MATERIALS AND METHODS
Patients. Eligible patients were X18 years old, with histo-
logically confirmed locally advanced unresectable or metastatic
adenocarcinoma of the colon or rectum, life expectancyX6 months,
and an Eastern Cooperative Oncology Group performance status
(ECOG PS) of p2. Patients were also required to have an EGFR-
detectable or EGFR-undetectable tumour (the option of tumour
biopsy was offered to patients without sufficient archived tumour
tissue to allow assessment of EGFR) and at least one unidimension-
ally measurable target lesion (X2 cm with conventional techniques
or X1 cm with spiral computed tomography (CT) scan). Adequate
haematological, hepatic, and renal function and recovery from the
effects of prior therapy were also required. Key patient exclusion
criteria included: prior systemic chemotherapy for locally advanced
unresectable CRC or mCRC (prior adjuvant chemotherapy was
allowed if progressive disease (PD) was documented 46 months
after the end of the last cycle of adjuvant chemotherapy or X12
months for oxaliplatin-containing regimens); prior radiotherapy to
425% of bone marrow (radiation therapy as a part of standard
adjuvant chemoradiotherapy for rectal cancer 46 months before
study entry was allowed); documented and/or symptomatic brain
metastases; previous therapy with mAbs or any EGFR-targeting
agent; current use of chronic non-topical corticosteroid treatment for
46 months at doses410mg per day of prednisolone or equivalent
before study entry, which in the opinion of the investigator could
compromise the patient or the study; known dihydropyrimidine
dehydrogenase deficiency; or acute or subacute intestinal occlusion.
The study was conducted in accordance with the ethical
principles of the Declaration of Helsinki and the International
Conference on Harmonisation and Good Clinical Practice. Study
procedures were approved by local ethic committees, and all
patients provided written informed consent.
Study design and treatment. This was an open-label, single-arm,
multicentre, phase II study investigating the efficacy and safety of
necitumumab in combination with mFOLFOX6 in the first-line
treatment of locally advanced CRC or mCRC. A treatment cycle
was defined as 2 weeks. On day 1 of each cycle, patients received
necitumumab at an absolute dose of 800mg, by i.v. infusion over
50min. The necitumumab infusion was followed by administration
of the mFOLFOX6 regimen (85mgm 2 i.v. oxaliplatin over 2 h;
400mgm 2 i.v. folinic acid over 2 h; and then 5-FU, 400mgm 2
i.v. bolus injection followed by 2400mgm 2 continuous i.v.
infusion over 46 h on days 1–2). Dose modifications as specified in
the study protocol were permitted in the event of treatment-related
toxicity. Radiographic evaluation (CT or magnetic resonance
imaging) of disease was performed every 8 weeks; treatment
continued until documentation of PD, development of unaccep-
table toxicity, protocol noncompliance, or withdrawal of consent.
For patients who discontinued treatment for reasons other than
PD, radiographic evaluation of disease continued at least every 3
months after discontinuation (until PD).
Endpoints and assessments. The primary endpoint was ORR,
based on best response determined by investigators according to
the Response Evaluation Criteria in Solid Tumors, Version 1.0
(Therasse et al, 2000). No central radiological review was carried
out. Responses (complete or partial) were to be confirmed at least 4
weeks after the criteria for response were first met.
Secondary endpoints included OS, PFS, duration of response,
pharmacokinetics, and safety. In addition, the association between
clinical outcome (ORR, OS, and PFS) following treatment and
tumour KRAS exon 2 mutation status (wild type vs mutant) and
EGFR mutation status and EGFR protein expression status
(positive vs negative) was evaluated.
Patient safety was evaluated at every treatment visit, based on
reported AEs, serious AEs, physical examinations, and laboratory
analyses. Adverse events were classified by type, incidence,
severity, and causality. The National Cancer Institute–Common
Terminology Criteria for Adverse Events, version 3.0, was used to
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grade all systemic and local AEs; all AE terms were coded using the
Medical Dictionary for Regulatory Activities (MedDRA 13.0).
Tumour KRAS exon 2 and EGFR mutation screening and EGFR
expression analysis were performed by Genzyme Genetics
(Los Angeles, CA, USA). Mutation detection was carried out on
DNA extracted from microdissected tumour sections prepared from
formalin-fixed paraffin-embedded (FFPE) archival samples (follow-
ing pathologist review) using an Arcturus PicoPure DNA extraction
kit (Applied Biosystems, Grand Island, NY, USA). KRAS mutations
(codons 12 and 13) were detected by PCR using the TheraScreen
K-RAS Mutation Kit (Qiagen, Hilden, Germany). Epidermal growth
factor receptor kinase domain mutation screening (EGFR exons 18–
21) was carried out by PCR and bi-directional sequencing (BigDye
v1.1, Applied Biosystems) on a 3130 Genetic Analyzer (Applied
Biosystems). Tumour EGFR expression was detected by immunohis-
tochemistry (IHC) performed on tissue sections prepared from FFPE
samples using the DAKO EGFR pharmDx IHC kit (Glostrup,
Denmark). Immunostained sections were evaluated by a pathol-
ogist according to manufacturer’s guidelines.
Pharmacokinetic parameters (Cmax, Tmax, AUC(0–tlast), AUC(0–N),
AUC(tlast–N), t½, CL, and Vss) were calculated using non-
compartmental methods (WinNonlin 5.3, Pharsight Corporation,
Cary, NC, USA) from serum concentrations over time following a
single dose of 800mg necitumumab co-administered with mFOL-
FOX6 on day 1 of cycle 1. Blood samples were collected before and
immediately after the initial necitumumab infusion, and at 1, 2, 4, 24
(day 2), 72 (day 4), 96 (day 5), 144 (day 7), 168 (day 8), and 236
(day 11) hours after infusion. From cycles 2–6, additional blood
samples were drawn immediately before and 1h after the end of
necitumumab infusion. Samples were also collected at the end of
therapy and 45 days after the final necitumumab infusion.
Statistical analysis and considerations. Primary and secondary
efficacy endpoints were evaluated in the modified intention to treat
(mITT) population, comprising all patients who were enrolled and
treated with any quantity of necitumumab or chemotherapy.
The study sample size was calculated using expected response rates
of 55% for necitumumab plus mFOLFOX6 and 32% for mFOLFOX6
alone, based on a previously reported response rate of 32% for
FOLFOX (Venook et al, 2006). Using a two-sided 95% confidence
interval (CI), it was estimated that enrolment of 40 evaluable patients
would give a power of 86% to detect a significant difference in ORR
between necitumumab plus mFOLFOX6 and the historical control.
The Kaplan–Meier method was used to estimate time to event
data (OS, PFS, and duration of response) with 95% CIs. Overall
survival was defined as the time from the first day of therapy to the
date of death; if the patient was alive at the end of the follow-up
period or was lost to follow-up, OS was censored on the last date
the patient was known to be alive. Progression-free survival was
defined as the time from the first day of therapy until the date of
PD or death, whichever was first. In the case where study treatment
results in tumour regression allowing for surgical resection, the PFS
analysis used the date of radiological progression determined by
the regular follow-up radiological assessments following the
surgical resection. If no progression was observed the patient was
censored at the last radiological assessment. Duration of response
was defined as the time from the day the measurement criteria
were met for a complete or partial response (whichever was first
recorded) until the first date of PD or death. Patients who neither
experienced PD nor died were censored at the date of their last
tumour assessment.
Exploratory subgroup analyses of ORR, OS, and PFS by tumour
KRAS exon 2 mutation status and EGFR expression status were
performed. The evaluation based on KRAS exon 2 mutation status
was not planned in the original study protocol (6 February 2007),
but was added in a protocol amendment (17 March 2008) for
tumour tissue samples submitted by patients who signed an
informed consent document specific to this evaluation. No other
substantive changes to the conduct of the study were made.
The database was locked for analysis on 31 March 2011. Data
analyses were performed using SAS 8.2 or higher.
RESULTS
Patients and treatment. A total of 44 patients were enrolled
between 01 August 2007 and 03 June 2008, at three sites in Spain
and two in Belgium; all 44 enrolled patients received at least one
dose of study therapy; the mITT population may therefore be
considered to be equivalent to a classical ITT population. All
patients discontinued study treatment, mostly due to PD (n¼ 18,
40.9%) or AEs (n¼ 10, 22.7%). Patient baseline and disease
characteristics are summarised in Table 1.
All patients had a diagnosis of adenocarcinoma, originating
from the colon (65.9%) or rectum (34.1%), and either metastatic
(95.5%) or locally advanced (two patients; 4.5%) disease at baseline.
The mean duration of disease (time from initial diagnosis to the
date of first dose of any study treatment) was 5.1 months (range:
0.3–42.8 months). The majority of patients (n¼ 41; 93.2%) had a
baseline ECOG PS of 0–1.
Table 1. Baseline characteristics in the ITT population
Characteristic N¼44
Sex
Male 25 (56.8)
Female 19 (43.2)
Race
White 42 (95.5)
Black 2 (4.5)
Age group
18 to o65 22 (50.0)
X65 22 (50.0)
Median age, years (range) 64.0 (33–81)
Duration of disease (months)
Mean (s.d.) 5.1 (9.8)
Median (range) 1.6 (0.3–42.8)
ECOG performance status
0 22 (50.0)
1 19 (43.2)
2 3 (6.8)
Disease
Locally advanced 2 (4.5)
Metastatic 42 (95.5)
Site of tumour origin
Colon 29 (65.9)
Rectum 15 (34.1)
Tumour grade
Well differentiated 8 (18.2)
Moderately differentiated 23 (52.3)
Poorly differentiated 4 (9.1)
Undifferentiated 0
Unknown 9 (20.5)
Tumour EGFR expression status (IHC)
Expressing 16 (36.4)
Negative 21 (47.7)
NA 2 (4.5)
Missing 5 (11.4)
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; IHC¼
immunohistochemistry; ITT¼ intention to treat; NA¼ not available. Data presented are n
(%) unless otherwise stated.
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Of the 44 enrolled patients, 33 (75.0%) received X80% of the
planned doses of necitumumab, oxaliplatin, and folinic acid; 26
patients (59.1%) received X80% of the planned dose of 5-FU
(Supplementary Table 1). The number of treatment delays of at
least 1 week was similar across all agents. No dose reductions were
required for necitumumab; 11.4% and 31.8% of patients required
X2 reductions to the dose of oxaliplatin and 5-FU, respectively.
Efficacy. All 44 patients in the ITT population were evaluable for
the best overall response. The ORR was 63.6% (95% CI 47.8–77.6),
including four patients (9.1%) with a complete response and
24 (54.5%) with a partial response (Table 2). An additional 15
patients (34.1%) had stable disease as best response, resulting in a
disease control rate of 97.7% (95% CI 88.0–99.9). The median
duration of response was 10.0 months (95% CI 7.0–16.0).
A total of 30 deaths were reported; 13 patients were alive at the
cut-off date (31 October 2010), and one was lost to follow-up. The
median OS was 22.5 months (95% CI 11.0–30.0). At 1- and 2-year
OS, the rates were 63.6% and 42.9%, respectively (Figure 1). In the
analysis of PFS, 31 events (documented PD or death) were
observed and 13 patients were censored (Figure 1); the median PFS
was 10.0 months (95% CI 7.0–12.0).
KRAS exon 2 tumour mutation status was evaluable in tumours
from 25 of the 44 enrolled patients (results were not available for
19 patients, either because adequate tumour tissue was not
available or the patient did not provide consent to the additional
analysis). KRAS codon 12 or 13 mutations were detected in the
tumours from 9 of these 25 patients (36.0%), and the tumours from
the remaining 16 patients (64.0%) were wild type at these loci.
The ORR was higher in patients with KRAS exon 2 wild-type
tumours (87.5%, 95% CI 61.7–98.4) compared with those with
KRAS exon 2 mutated tumours (55.6%, 95% CI 21.2–86.3), with all
Table 2. Disease response in the ITT population and in
patients grouped by tumour KRAS mutation status
KRAS evaluable patients
(N¼25)a
Parameter ITT (N¼44)
KRAS wild type
(n¼16)
KRAS mutant
(n¼9)
Best overall response, n (%)
Complete response 4 (9.1) 4 (25.0) 0
Partial response 24 (54.5) 10 (62.5) 5 (55.6)
Stable disease 15 (34.1) 2 (12.5) 4 (44.4)
Progressive disease 1 (2.3) 0 0
Not evaluable 0 0 0
ORR, n (%) 28 (63.6) 14 (87.5) 5 (55.6)
95% CI 47.8–77.6 61.7–98.4 21.2–86.3
DCR, n (%) 43 (97.7) 16 (100) 9 (100)
95% CI 88.0–99.9 79.4–100 66.4–100
Abbreviations: CI¼ confidence interval; DCR¼disease control rate; ITT¼ intention to treat;
ORR¼objective response rate.
aMissing in 19 patients.
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Figure 1. Overall survival and progression free survival data in the ITT population. Kaplan–Meier plots showing overall survival (A) and
progression-free survival (B) in the intention to treat population.
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four complete responses reported in the study occurring in patients
with KRAS exon 2 wild-type tumours. Overall survival (median
30.0 months (95% CI 23–NA) vs 7.0 months (95% CI 5.0–37.0))
and PFS (median 12.0 months (95% CI 8.0–20.0) vs 7.0 months
(95% CI 4.0–18.0)) were also longer among patients with KRAS
exon 2 wild-type tumours compared with those with KRAS exon 2
mutant tumours (Figure 2).
No EGFR kinase domain mutations were detected in any of the
tumours from 36 patients evaluable for EGFR tumour mutation
status.
Tumour EGFR protein expression status was evaluable for 37 of
the 44 enrolled patients; data were missing for five patients, and the
analysis was not performed for two patients. A total of 16 (43.2%)
of 37 patients had tumours that were positive for EGFR expression
by IHC; 21 (56.8%) had tumours that were EGFR negative. Overall,
there were no significant differences between these subgroups for
any of the efficacy parameters evaluated. The ORR was 62.5%
(95% CI 35.4–84.8) among patients with EGFR-expressing
tumours and 66.7% (95% CI 43.0–85.4) among those whose
tumours were negative for EGFR expression. Median OS (25.5
months vs 24.0 months) and median PFS (11.0 months vs 10.0
months) were also similar between these subgroups.
Safety. Treatment-emergent AEs of any grade were reported in all
treated patients. Grade X3 events were reported in 38 (86.4%)
patients; the most common of these events were neutropenia
(29.5%), asthenia (27.3%), and rash (20.5%) (Table 3). Grade 4 AEs
were reported for seven patients (15.9%). Six of these seven
patients had grade 4 AEs considered to be related to study
treatment by the investigator, including four patients with grade 4
neutropenia and one patient each with sepsis and febrile
neutropenia. In addition, one patient was reported with grade 4
hypocalcaemia (considered to be not related to study treatment).
Consistent with prior evidence that skin toxicity is a class effect
of EGFR mAbs, 41 patients (93.2%) experienced some form of skin
or subcutaneous disorder regardless of grade or relationship to
study therapy. This included five patients (11.4%) with acneform
dermatitis and 31 patients (70.5%) with rash. Skin toxicity was
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Figure 2. Overall survival and progression free survival data in the ITT population. Kaplan–Meier plots showing overall survival (A) and
progression-free survival (B) in patients with KRAS wild-type or KRAS mutated tumours.
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grade 3 in a total of 13 patients (29.5%), including 1 of 5 patients
with acneform dermatitis (2.3%) and 9 of 31 with rash (20.5%).
In all patients, rash and acneform dermatitis were considered at
least possibly related to necitumumab. Conjunctivitis was observed
in 11 patients (25.0%), and was grade 3 in one (2.3%); 9 of 11
patients had conjunctivitis considered at least possibly related to
necitumumab (including the patient with grade 3 conjunctivitis).
In addition, 10 patients (22.7%) experienced palmar-plantar
erythrodysesthesia syndrome (including two patients (4.5%) of
grade 3); necitumumab-related palmar-plantar erythrodysesthesia
syndrome was reported in 7 (15.9%) patients (including 1 (2.3%)
with grade 3).
Regarding AEs of special interest, hypersensitivity reactions
were reported in three patients (6.8%); these included one serious
grade 2 AE that was considered to be related to necitumumab, and
one grade 1 and one grade 2 AE that were considered to be related
to chemotherapy. Conjunctivitis of any grade was reported in 11
patients (25.0%); events were considered to be related to
necitumumab for nine of these patients, including one with a
grade 3 event. Hypomagnesaemia was reported in five patients
overall; three patients experienced grade p2 hypomagnesaemia
considered to be related to necitumumab. Thromboembolic AEs
were reported in nine patients (20.5%), including six patients with
grade 2 events and three patients with grade 3 events. Of these AEs,
only one (grade 2 thrombosis in device) was considered to be at
least possibly related to necitumumab.
Adverse events commonly associated with exposure to oxali-
platin-based chemotherapy included: neutropenia (52.3%; grade
X3, 29.5%), thrombocytopenia 11.4% (all grade 1–2), and
peripheral sensory neuropathy (22.7%; grade 3, 9.1%). All of
these AEs were considered to be at least possibly related to study
therapy.
Treatment discontinuations due to AEs (primary cause) were
reported in 10 (22.7%) patients; these included one patient each
with grade 1 thrombocytopenia, persistent grade 2 mucositis,
grade 2 asthenia (worsening) with grade 2 neuropathy, grade 2
paraesthesia, grade 3 dizziness, grade 3 vomiting, grade 3 fatigue,
and grade 3 asthenia. This group also included two patients who
died due to an AE (grade 5 event), one from respiratory failure and
one from intestinal obstruction. In total, there were three grade 5
treatment-emergent AEs in this study, including one additional
patient with respiratory failure (including organising pneumonia).
Two additional deaths, one due to intestinal obstruction and one
due to respiratory failure secondary to pneumonia, were not
reported as treatment-emergent AEs as they occurred 430 days
after the last dose of study therapy. Twenty-five additional deaths
occurred 430 days after the last dose of study therapy due to PD,
including one patient whose death was deemed to be due to general
health deterioration, which was considered secondary to PD. None
of the reported deaths were considered to be related to any study
therapy.
Pharmacokinetics. Following infusion of 800mg necitumumab
on day 1 of cycle 1, at least one sample for pharmacokinetic
analysis was collected from 43 of 44 enrolled patients, with data
available from 42 (95.5%) patients. Data from three patients were
excluded due to high pre-dose concentrations or limited available
data points. Summary data for the non-compartmental analysis of
the necitumumab pharmacokinetic parameters are shown in
Supplementary Table 2. The geometric mean Cmax was 344mgml
 l
(coefficient of variation (CV)¼ 46%) following single-dose admin-
istration. The geometric means of estimated half-life and clearance
were 142 h (range 99.8–299) and 20.3ml h l (CV¼ 35%),
respectively. Following multiple-dose administration (800mg every
2 weeks), geometric mean (CV%) trough levels appeared to reach a
plateau after 4–5 cycles, ranging from 59.1 (60) to 75.4 (64)
mgml 1 (Supplementary Figure 1). Data from a pre-clinical
study indicated that necitumumab was effective at or above
trough concentrations of 40 mgml 1. The median trough con-
centration observed in the current study exceeded this target level
from cycle 3.
DISCUSSION
This phase II study was designed to evaluate the efficacy and safety
of the second-generation human EGFR mAb necitumumab in
combination with mFOLFOX6 in previously untreated patients
with locally advanced or metastatic CRC. The study was initiated at
Table 3. Treatment-emergent adverse events in the ITT
population (N¼44)
Adverse eventa Any grade Grade X3
Any 44 (100) 38 (86.4)
Blood and lymphatic disorders
Neutropenia 23 (52.3) 13 (29.5)
Anaemia 9 (20.5) 1 (2.3)
Thrombocytopenia 5 (11.4) 0
Eye disorders
Conjunctivitis 11 (25.0) 1 (2.3)
Gastrointestinal disorders
Diarrhoea 24 (54.5) 4 (9.1)
Nausea 17 (38.6) 1 (2.3)
Vomiting 16 (36.4) 3 (6.8)
Constipation 13 (29.5) 1 (2.3)
Stomatitis 8 (18.2) 0
Abdominal pain upper 5 (11.4) 0
Dyspepsia 5 (11.4) 0
Internal obstruction 4 (9.1) 4 (9.1)
General disorders and administration site conditions
Asthenia 36 (81.8) 12 (27.3)
Mucosal inflammation 19 (43.2) 2 (4.5)
Pyrexia 10 (22.7) 0
Infections and infestations
Paronychia 16 (36.4) 1 (2.3)
Investigations
Weight decreased 14 (31.8) 0
Weight increased 7 (15.9) 0
Metabolism and nutrition disorders
Decreased appetite 18 (40.9) 2 (4.5)
Hypomagnesaemia 5 (11.4) 0
Musculoskeletal and connective tissue disorders
Back pain 8 (18.2) 1 (2.3)
Nervous system disorders
Paraesthesia 16 (36.4) 6 (13.6)
Dysaesthesia 13 (29.5) 4 (9.1)
Peripheral sensory neuropathy 10 (22.7) 4 (9.1)
Neurotoxicity 9 (20.5) 1 (2.3)
Dysgeusia 7 (15.9) 0
Respiratory, thoracic, and mediastinal disorders
Dyspnoea 5 (11.4) 0
Skin and subcutaneous tissue disorders
Rash 31 (70.5) 9 (20.5)
Alopecia 10 (22.7) 0
Palmar-plantar erythrodysaesthesia syndrome 10 (22.7) 2 (4.5)
Skin fissures 10 (22.7) 2 (4.5)
Dry skin 8 (18.2) 0
Dermatitis acneiform 5 (11.4) 1 (2.3)
Pruritus 5 (11.4) 0
Abbreviation: ITT¼ intention to treat.
aData presented are n (%) according to preferred terms in order of system organ class
coded by Medical Dictionary for Regulatory Activities for any grade occurring in X10% of
patients or for grade X3 occurring in X5% of patients.
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a time when other EGFR mAbs (cetuximab and panitumumab)
were also in clinical development.
The majority of the 44 treated patients (95.5%) had metastatic
disease; baseline demographic and disease characteristics were
generally comparable with those reported for other studies
investigating chemotherapy in combination with targeted agents
in previously untreated patients with mCRC (Tabernero et al,
2007; Hochster et al, 2008; Bokemeyer et al, 2009). Pharmacoki-
netic analysis of necitumumab largely confirmed the findings
reported from the phase I study of necitumumab in patients with
solid malignancies (Kuenen et al, 2010), with target trough
concentrations (X40 mgml l) achieved in most patients after
three cycles of treatment. The data suggest that co-administration
of mFOLFOX6 had no relevant impact on the pharmacokinetic
characteristics of necitumumab.
In the ITT population, the primary endpoint of ORR was 63.6%
(95% CI 47.8–77.6); this compared favourably with the ORR of
41% (95% CI 27–56) measured in unselected patients with mCRC
receiving mFOLFOX6 alone in the randomised phase III TREE
study (Hochster et al, 2008). Similarly, OS in the present study
compared favourably (median 22.5 months, 95% CI 11.0–30.0)
with that reported in the TREE study (19.2 months, 95% CI 14.2–24.9).
Response rates in the current study were also comparable with
those reported in studies of cetuximab in combination with
FOLFOX regimens (44.8–72%) in unselected patients with mCRC
(Tabernero et al, 2007; Bokemeyer et al, 2009; Boccia et al, 2010;
Colucci et al, 2010). In addition, the secondary endpoints of OS
and PFS in the current study were also comparable with those
reported from these previous studies in this setting.
The effect of tumour mutations in KRAS codons 12 or 13 on the
efficacy of necitumumab in combination with mFOLFOX6 was
studied in 25 evaluable patients. The number of patients studied
was small, and the findings should be treated with caution.
However, there was a tendency towards a higher ORR (87.5% vs
55.6%), longer PFS (median 12.0 vs 7.0 months), and longer OS
(median 30.0 vs 7.0 months) among patients whose tumours were
KRAS exon 2 wild type compared with those whose tumours
harboured KRAS exon 2 mutations. These findings support those
from other single-arm studies of EGFR mAbs in previously treated
(Di Fiore et al, 2007; De Roock et al, 2008; Lievre et al, 2008) and
untreated patients (Colucci et al, 2010), which were later confirmed
in larger randomised studies of first-line FOLFOX4 in combination
with either cetuximab or panitumumab (Bokemeyer et al, 2011;
Douillard et al, 2014). Further investigation is required to assess
whether mutations at other RAS loci are negative predictors of
efficacy for necitumumab in combination with a FOLFOX
regimen, as has been reported for cetuximab and panitumumab
(Douillard et al, 2013; Bokemeyer et al, 2015).
In further subgroup analyses, no relevant differences were
reported for any of the studied efficacy endpoints in patients whose
tumours were positive for EGFR expression compared with those
whose tumours were negative. Thus, it appears that EGFR
expression as detected by IHC is not a requirement for the
efficacy of necitumumab in combination with chemotherapy,
consistent with findings from other studies evaluating cetuximab
(Chung et al, 2005; Folprecht et al, 2010; Brodowicz et al, 2013;
Licitra et al, 2013).
The safety profile of necitumumab in combination with
mFOLFOX6 was generally comparable with those reported for
other EGFR mAbs when used in combination with FOLFOX
regimens (Tabernero et al, 2007; Folprecht et al, 2010; Ocvirk et al,
2010; Bokemeyer et al, 2011; Brodowicz et al, 2013; Douillard et al,
2014; Wasan et al, 2014). The most common grade X3 AEs were
primarily class effects reflecting exposure to this treatment
combination, including gastrointestinal disorders (diarrhoea
9.1%), blood and lymphatic disorders (neutropenia, 29.5%),
nervous system disorders (paraesthesia 13.6%), and skin toxicities
(rash 20.5%). In line with expectations for a human antibody, the
incidence of hypersensitivity reactions was low: reported in only
three patients (one at grade 1, two at grade 2), the grade 2 reaction
in one patient was considered to be related to necitumumab.
Notably, venous thromboembolic events have previously been
associated with the administration of EGFR antibodies in
combination with chemotherapy (Petrelli et al, 2012). Of the eight
thromboembolic events reported in the current study, none were
grade 43 and only one was considered to be possibly related to
necitumumab. There were no reports of cardiac ischaemia. Of note,
the incidence of grade X3 asthenia (27.3%) was somewhat higher
than generally reported in other studies of EGFR mAbs in
combination with FOLFOX regimens. Adverse events leading to
treatment discontinuation were reported in 10 (22.7%) patients
and none of the 30 reported deaths were considered to be
treatment related.
In summary, the combination of necitumumab with mFOL-
FOX6 was associated with evidence of efficacy and a manageable
safety profile in patients with previously untreated locally advanced
or metastatic CRC. Clinical outcome was better in patients with
KRAS exon 2 wild type compared with KRAS exon 2 mutant
tumours. The efficacy of this combination appears to be at least
comparable with other EGFR antibodies approved for use in
combination with first-line oxaliplatin-based chemotherapy in
patients with mCRC. Although cross-trial comparisons should
be treated with caution, the data suggest that combining
necitumumab with mFOLFOX6 has the potential to provide
additional benefit in this setting. Further investigation of
necitumumab with oxaliplatin-based chemotherapy in patients
with tumours wild type for RAS is required if this EGFR mAb is to
be added to the therapeutic armamentarium of mCRC.
ACKNOWLEDGEMENTS
We thank the patients, their families, and the study personnel
across all sites for participating in this study. Paul Hoban of Cancer
Communications and Consultancy Ltd, Knutsford, UK and Frank
Ferrara of Eli Lilly and Company, Bridgewater, USA, provided
writing assistance. Anastasia Perkowski of Eli Lilly and Company,
Bridgewater, USA, provided editorial assistance. The study sponsor
was Eli Lilly and Company. The study is registered with
the European Union clinical trials register EudraCT number
2006-003147-23.
CONFLICT OF INTEREST
JS declared receiving honoraria from Lilly, Merck Serono, Roche,
Amgen, Sanofi, and Bayer; and research funding from Merck
Serono and Bayer. AC declared receiving honoraria from Lilly,
Merck Serono, Roche, Amgen, and Bayer; and research funding
from Roche, Merck Serono, and Bayer. AH declared receiving
honoraria from Ipsen, Bayer, and Roche; and research funding
from Bayer, Novartis, Roche, and Sirtex. RV, GC, and JW are
employees of Eli Lilly and Company. JT declared consultant/
advisory board for Amgen, Boehringer Ingelheim, Celgene, Chugai,
Imclone, Lilly, Merck, Merck Serono, Millennium, Sanofi,
Symphogen, and Taiho. The remaining authors declare no conflict
of interest.
REFERENCES
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T,
Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008)
BRITISH JOURNAL OF CANCER Necitumumab plus mFOLFOX6 in colorectal cancer
378 www.bjcancer.com |DOI:10.1038/bjc.2015.480
Wild-type KRAS is required for panitumumab efficacy in patients with
metastatic colorectal cancer. J Clin Oncol 26(10): 1626–1634.
Boccia RV, Cosgriff TM, Headley DL, Badarinath S, Dakhil SR (2010)
A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of
patients with metastatic colorectal cancer. Clin Colorectal Cancer 9(2):
102–107.
Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A,
Celik I, Schlichting M, Koralewski P (2011) Efficacy according to
biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for
metastatic colorectal cancer: the OPUS study. Ann Oncol 22(7):
1535–1546.
Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J,
de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A,
Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and
without cetuximab in the first-line treatment of metastatic colorectal
cancer. J Clin Oncol 27(5): 663–671.
Bokemeyer C, Kohne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U,
Beier F, Duecker K, van Krieken JH, Tejpar S (2015) FOLFOX4 plus
cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer
51: 1243–1252.
Brodowicz T, Ciuleanu TE, Radosavljevic D, Shacham-Shmueli E, Vrbanec D,
Plate S, Mrsic-Krmpotic Z, Dank M, Purkalne G, Messinger D,
Zielinski CC (2013) FOLFOX4 plus cetuximab administered weekly or
every second week in the first-line treatment of patients with KRAS
wild-type metastatic colorectal cancer: a randomized phase II CECOG
study. Ann Oncol 24(7): 1769–1777.
Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A,
Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP,
Saltz LB (2005) Cetuximab shows activity in colorectal cancer patients
with tumors that do not express the epidermal growth factor receptor by
immunohistochemistry. J Clin Oncol 23(9): 1803–1810.
Colucci G, Giuliani F, Garufi C, Mattioli R, Manzione L, Russo A, Lopez M,
Parrella P, Tommasi S, Copetti M, Daniele B, Pisconti S, Tuveri G,
Silvestris N, Maiello E (2010) Cetuximab plus FOLFOX-4 in untreated
patients with advanced colorectal cancer: a Gruppo Oncologico
dell’Italia Meridionale Multicenter phase II study. Oncology 79(5–6):
415–422.
De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G,
Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y,
Van Cutsem E, Tejpar S (2008) KRAS wild-type state predicts survival and
is associated to early radiological response in metastatic colorectal cancer
treated with cetuximab. Ann Oncol 19(3): 508–515.
Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP,
Bastit L, Killian A, Sesboue R, Tuech JJ, Queuniet AM, Paillot B,
Sabourin JC, Michot F, Michel P, Frebourg T (2007) Clinical relevance of
KRAS mutation detection in metastatic colorectal cancer treated by
Cetuximab plus chemotherapy. Br J Cancer 96(8): 1166–1169.
Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M,
Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I,
Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M,
Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD (2013)
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal
cancer. N Engl J Med 369(11): 1023–1034.
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M,
Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I,
Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M,
Oliner KS, Tian Y, Xu F, Sidhu R (2014) Final results from PRIME:
randomized phase III study of panitumumab with FOLFOX4 for
first-line treatment of metastatic colorectal cancer. Ann Oncol 25(7):
1346–1355.
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M,
Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I,
Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M,
Oliner KS, Wolf M, Gansert J (2010) Randomized, phase III trial of
panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin
(FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with
previously untreated metastatic colorectal cancer: the PRIME study. J Clin
Oncol 28(31): 4697–4705.
Ferlay J, Soerjomataram I I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M,
Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0,
Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11.
Available at http://globocan.iarc.fr (accessed on 14 April 2015).
Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F,
Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R,
Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F,
Kohne CH (2010) Tumour response and secondary resectability of
colorectal liver metastases following neoadjuvant chemotherapy with
cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11(1):
38–47.
Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD,
Cohn AL, Wong L, Fehrenbacher L, Abubakr Y, Saif MW, Schwartzberg L,
Hedrick E (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine
regimens with or without bevacizumab as first-line treatment of metastatic
colorectal cancer: results of the TREE study. J Clin Oncol 26(21):
3523–3529.
Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D,
Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ,
Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras
mutations and benefit from cetuximab in advanced colorectal cancer.
N Engl J Med 359(17): 1757–1765.
Kuenen B, Witteveen PO, Ruijter R, Giaccone G, Dontabhaktuni A, Fox F,
Katz T, Youssoufian H, Zhu J, Rowinsky EK, Voest EE (2010) A phase I
pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1
monoclonal antibody directed against EGFR in patients with advanced
solid malignancies. Clin Cancer Res 16(6): 1915–1923.
Licitra L, Storkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR,
Vermorken JB, von Heydebreck A, Esser R, Celik I, Ciardiello F (2013)
Predictive value of epidermal growth factor receptor expression for
first-line chemotherapy plus cetuximab in patients with head and neck
and colorectal cancer: analysis of data from the EXTREME and CRYSTAL
studies. Eur J Cancer 49(6): 1161–1168.
Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M,
Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P,
Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P (2008)
KRAS mutations as an independent prognostic factor in patients with
advanced colorectal cancer treated with cetuximab. J Clin Oncol 26(3):
374–379.
Liu M, Zhang H, Jimenez X, Ludwig D, Witte L, Bohlen P, Hicklin DJ, Zhu Z
(2004) Identification and characterization of a fully human antibody
directed against epidermal growth factor receptor for cancer therapy.
Cancer Res 64: 163.
Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH,
Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A,
Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D,
Kaplan R, Cheadle JP; MRC COIN Trial Investigators (2011) Addition of
cetuximab to oxaliplatin-based first-line combination chemotherapy for
treatment of advanced colorectal cancer: results of the randomised phase 3
MRC COIN trial. Lancet 377(9783): 2103–2114.
NCCN. Clinical practice guidelines in oncology (NCCN guidelines): colon
cancer; Version 2.2015. Available at http://www.nccn.org/professionals/
physician_gls/pdf/colon.pdf (accessed 3 August 2015).
Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I,
Papai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D,
Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R,
Scheithauer W, Zielinski CC (2010) Cetuximab plus FOLFOX6 or
FOLFIRI in metastatic colorectal cancer: CECOG trial. World J
Gastroenterol 16(25): 3133–3143.
Petrelli F, Cabiddu M, Borgonovo K, Barni S (2012) Risk of venous and
arterial thromboembolic events associated with anti-EGFR agents: a meta-
analysis of randomized clinical trials. Ann Oncol 23(7): 1672–1679.
Prewett M, Tonra JR, Rajiv B, Hooper AT, Makhoul G, Finnerty B, Witte L,
Bohlen P, Zhu Z, Hicklin DJ (2004) Antitumor activity of a novel, human
anti-epidermal growth factor receptor (EGFR) monoclonal antibody
(IMC-11F8) in human tumor xenograft models. Proc Am Soc Clin Oncol
45: Abstract 5353.
Tabernero J, Van Cutsem E, Diaz-Rubio E, Cervantes A, Humblet Y, Andre T,
Van Laethem JL, Soulie P, Casado E, Verslype C, Valera JS, Tortora G,
Ciardiello F, Kisker O, de Gramont A (2007) Phase II trial of cetuximab
in combination with fluorouracil, leucovorin, and oxaliplatin in the
first-line treatment of metastatic colorectal cancer. J Clin Oncol 25(33):
5225–5232.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS,
Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT,
Christian MC, Gwyther SG (2000) New guidelines to evaluate the
response to treatment in solid tumors. European Organization for
Necitumumab plus mFOLFOX6 in colorectal cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.480 379
Research and Treatment of Cancer, National Cancer Institute of the
United States, National Cancer Institute of Canada. J Natl Cancer Inst
92(3): 205–216.
Van Cutsem E, Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines
Working Group (2014) Metastatic colorectal cancer: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol
25(Suppl 3): iii1–iii9.
Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S,
Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A,
Celik I, Rougier P, Ciardiello F (2011) Cetuximab plus irinotecan,
fluorouracil, and leucovorin as first-line treatment for metastatic colorectal
cancer: updated analysis of overall survival according to tumor KRAS and
BRAF mutation status. J Clin Oncol 29(15): 2011–2019.
Venook A, Niedzwiecki D, Hollis D, Sutherland S, Goldberg R, Alberts S,
Benson A, Wade J, Schilsky R, Mayer R (2006) Phase III study of
irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV
(FOLFOX)±cetuximab for patients (pts) with untreated metastatic
adenocarcinoma of the colon or rectum (MCRC): CALGB 80203
preliminary results. J Clin Oncol 24(18S): Abstract 3509.
Wasan H, Meade AM, Adams R, Wilson R, Pugh C, Fisher D, Sydes B,
Madi A, Sizer B, Lowdell C, Middleton G, Butler R, Kaplan R,
Maughan T (2014) Intermittent chemotherapy plus either intermittent
or continuous cetuximab for first-line treatment of patients with
KRAS wild-type advanced colorectal cancer (COIN-B): a randomised
phase 2 trial. Lancet Oncol 15(6): 631–639.
This work is licensed under the Creative
CommonsAttribution 4.0 International License.
To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
BRITISH JOURNAL OF CANCER Necitumumab plus mFOLFOX6 in colorectal cancer
380 www.bjcancer.com |DOI:10.1038/bjc.2015.480
